Pelthos Therapeutics Inc. reports a Return on Equity (ROE) of -146.97%.

What is PTHS's dividend yield?

Pelthos Therapeutics Inc. offers a dividend yield of 0.00%.

What is PTHS's Quality Score?

Our AI rates PTHS's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PTHS?

Our AI Timing Score for PTHS is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PTHS belong to?

Pelthos Therapeutics Inc. is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange

Pelthos Therapeutics Inc. (PTHS) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

PTHS AI Analysis Summary

Our AI summary for PTHS: Pelthos Therapeutics Inc. (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at ROE of -146.97%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PTHS

Pelthos Therapeutics Inc.

US:NYSE MKT STOCK Healthcare >> Biotechnology News 96

USD 28.54

1.84 (6.89%) Day Change

Watchlist Portfolio Compare Chart

0.68

D/E

-147.0%

ROE

-35.5%

ROA

0.00%

Div Yield

PELTHOS THERAPEUTICS INC.
TYPE: STOCK
MARKET: NYSE MKT

Compare Watchlist Myport

USD 28.54 Price 1.84 (6.89%) Day Change	NEWS SCORE: 96

PTHS, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	96
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	28.54
PBV / Sector	2.64 / 44,105.10
Earning Per Share	-15.87

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	2.76 M GREAT
Average 1W Daily Value	5.76 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-186.23 / 97.23
NPM Average (%) / Sector	-222.08 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-35.49 / 185,260.64
ROA Average (%) / Sector	-2,554.21 / 36,684.64
ROA Change Average (%) / Sector	-27.09 / 422,221.42
ROE (%) / Sector	-146.97 / 243,761.81
ROE Average (%) / Sector	43.12 / 48,758.38 GREAT
ROE Change Average (%) / Sector	30.62 / 424,967.86 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:32
Symbol	PTHS
Name	PELTHOS THERAPEUTICS INC.
Sector	Healthcare >> Biotechnology
Market	NYSE MKT
Listed Shares	3.48 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	92.80 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 4020 Stirrup Creek Drive, Durham, NC, United States, 27703

Phone: 919 908 2400

Website: https://pelthos.com

Employees: 92

Sector: Healthcare >> Biotechnology

Description: Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.